In this study, we elucidate the anticancer properties of selective HDAC6 inhibitors in renal cancer cell lines, shedding light on their potential therapeutic efficacy and paving the way for further exploration into their clinical application. This evidence concerns the gene HDAC6 and renal carcinoma.